Weekly cis-diamminedichloroplatinum II as induction chemotherapy in recurrent carcinoma of the cervix.
Twenty-four evaluable patients with recurrent carcinoma of the cervix after previous pelvic irradiation were treated with cis-diamminedichloroplatinum II (cis-DDP). Of the 14 patients who received low-dose (1 mg/kg) weekly induction cis-DDP, 10 (71%) responded, 6 (43%) of which were complete responses. Four (40%) of the ten patients who received high-dose (100 mg/m2) monthly cis-DDP responded, two of which were complete responses. Maintenance of these responses by combination chemotherapy which includes cis-DDP remains a significant problem.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011446:Prospective Studies; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery
D002945:Cisplatin